RLYB
NASDAQ
$16.71
Rallybio Corp (RLYB)
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, especially within immunology and hematology. The company boasts a promising pipeline of biologic drug candidates that are currently advancing through clinical trials, backed by an experienced management team with significant industry expertise. By forming strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, demonstrating its commitment to improving patient outcomes. With a well-defined strategy and a robust developmental framework, Rallybio is strategically positioned to achieve significant milestones in the healthcare sector.
Sector:
Healthcare
Industry:
Biotechnology
Target: $8 (-52.12%)
Market Cap
$85M
Free Cash Flow Yield
-32.33%
Beta (5Y)
0.96
Price Chart
Valuation
Market Cap$85M
P/S109.04
P/B1.85
Profitability
Total Revenue (TTM)$858K
Gross Profit (TTM)-$15M
EBITDA-$32M
Operating Margin-3787%
EPS-$1.48
Financial Health
Free Cash Flow Yield-32.33%
Growth & Risk
Beta (5Y)0.96
Sharpe Ratio1.99